Ribonuclease (3.1.4) Patents (Class 435/199)
-
Patent number: 8216567Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.Type: GrantFiled: September 13, 2011Date of Patent: July 10, 2012Assignee: Quintessence Biosciences, Inc.Inventors: Tony Klink, John Kink, Laura Strong
-
Publication number: 20120164125Abstract: A nucleic acid cleaving agent having a cleaving activity specific to a desired cleavage site in a nucleic acid such as large DNA, which comprises (1) a nucleic acid cleaving moiety, and (2) at least two zinc finger proteins bound to the nucleic acid cleaving moiety, wherein at least one of the zinc finger proteins can specifically bind to a nucleotide sequence located upstream from the target cleavage site, and at least one of the remaining zinc finger proteins can specifically bind to a nucleotide sequence located downstream from the target cleavage site.Type: ApplicationFiled: March 7, 2007Publication date: June 28, 2012Applicant: KYOTO UNIVERSITYInventor: Takashi Sera
-
Patent number: 8206965Abstract: This patent application relates to hybrid and/or single-chain rare-cutting endonucleases, called meganucleases, which recognize and cleave a specific nucleotide sequence, to polynucleotide sequences encoding for said rare-cutting endonucleases, to a vector comprising one of said polynucleotide sequences, to a cell or animal comprising one of said polynucleotide sequences or said rare-cutting endonucleases, to a process for producing one of said rare-cutting endonucleases and any use of the disclosed products and methods. More particularly, this invention contemplates any use of such rare-cutting endonuclease for genetic engineering and gene therapy.Type: GrantFiled: March 14, 2003Date of Patent: June 26, 2012Assignee: Cellectis S.A.Inventors: Sylvain Arnould, Patrick Chames, Andre Choulika, Jean-Charles Epinat, Emmanuel Lacroix
-
Publication number: 20120159659Abstract: New rare-cutting endonucleases, also called custom-made meganucleases, which recognize and cleave a specific nucleotide sequence, derived polynucleotide sequences, recombinant vector cell, animal, or plant comprising said polynucleotide sequences, process for producing said rare-cutting endonucleases and any use thereof, more particularly, for genetic engineering, antiviral therapy and gene therapy.Type: ApplicationFiled: September 28, 2010Publication date: June 21, 2012Inventors: Sylvain Arnould, Sylvia Bruneau, Jean-Pierre Cabaniols, Patrick Chames, André Choulika, Philippe Duchateau, Jean-Pierre Epinat, Agnès Gouble, Emmanuel Lacroix, Frédéric Paques, Christophe Perez-Michaut, Julianne Smith, David Sourdive
-
Publication number: 20120156753Abstract: The present invention provides novel compositions, kits and methods employing RNA 5? polyphosphatases, RNA 5? monophosphatases, capping enzymes, decapping enzymes, nucleic acid pyrophosphatases and RNA ligases, as well as other enzymes, for selective 5? ligation tagging of desired classes of RNA molecules that differ with respect to particular chemical moieties on their 5? ends. The 5? tagged RNA molecules can be used for synthesis of tagged first-stand cDNA, double-stranded cDNA, and sense or antisense RNA for a variety of uses.Type: ApplicationFiled: February 29, 2012Publication date: June 21, 2012Applicant: ILLUMINA, INC.Inventors: Jerome Jendrisak, Ramesh Vaidyanathan, Gary Dahl
-
Publication number: 20120149880Abstract: The invention provides a nucleic acid cassette comprising components in the following structure: A-B-C, wherein “A” is a nucleic acid sequence encoding a light chain of a first antibody (or antigen binding domain thereof), “B” is a nucleic acid sequence encoding a 2A peptide, “C” is a nucleic acid sequence encoding a heavy chain of a second antibody (or antigen binding domain thereof), and “-” is a phosphodiester or phosphorothioate bond. Also provided is a nucleic acid cassette with the structure A-p-B-C, where “p” is a nucleic acid encoding a protease recognition site, Also provided are methods for making recombinant antibodies using the nucleic acid cassette of the invention, cells and vector comprising the nucleic acid cassette of the invention, and kits for making the nucleic acid cassette of the invention.Type: ApplicationFiled: August 20, 2010Publication date: June 14, 2012Applicant: CELL SIGNALING TECHNOLOGY, INC.Inventors: Wan Cheung Cheung, Shuji Sato, Roberto Polakiewicz
-
Publication number: 20120141590Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.Type: ApplicationFiled: September 30, 2011Publication date: June 7, 2012Inventors: Michael Malakhov, Fang Fang
-
Publication number: 20120135498Abstract: A method for producing a nuclease of a gram negative bacterium or a nuclease preparation containing a nuclease of a gram negative bacterium including expression of the nuclease in a gram positive bacterium and subsequent secretion of the nuclease, as well as a nuclease or a nuclease preparation that can be obtained by this method.Type: ApplicationFiled: February 2, 2012Publication date: May 31, 2012Applicant: c-LEcta GmbHInventors: Thomas GREINER-STOEFFELE, Stefan Schoenert
-
Publication number: 20120129218Abstract: The present invention relates to a host cell comprising a cofilin-specific small interfering RNA (siRNA) sequence. The host cell may further comprise a nucleic acid encoding a recombinant protein. The present invention also relates to a method for producing a recombinant protein by the host cell comprising a cofilin-specific small interfering RNA (siRNA) sequence.Type: ApplicationFiled: November 11, 2011Publication date: May 24, 2012Applicant: UNIVERSITY OF DELAWAREInventors: KELVIN H. LEE, STEPHANIE HAMMOND
-
Patent number: 8183012Abstract: This invention provides compositions and methods for generating components of protein biosynthetic machinery including orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases. Methods for identifying orthogonal pairs are also provided. These components can be used to incorporate unnatural amino acids into proteins in vivo.Type: GrantFiled: December 10, 2004Date of Patent: May 22, 2012Assignees: The Scripps Research Institute, The Regents of the University of CaliforniaInventors: Peter G. Schultz, Lei Wang, John Christopher Anderson, Jason Chin, David R. Liu, Thomas J. Magliery, Eric L. Meggers, Ryan Aaron Mehl, Miro Pastrnak, Steven William Santoro, Zhiwen Zhang
-
Patent number: 8182991Abstract: The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to improved cleavage means for the detection and characterization of nucleic acid sequences. Structure-specific nucleases derived from a variety of thermostable organisms are provided. These structure-specific nucleases are used to cleave target-dependent cleavage structures, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.Type: GrantFiled: October 6, 2000Date of Patent: May 22, 2012Assignee: Third Wave Technologies, Inc.Inventors: Michael W. Kaiser, Victor I. Lyamichev, Natasha Lyamicheva
-
Publication number: 20120100597Abstract: The present invention provides compositions and methods for purifying RNA-free DNA from a sample.Type: ApplicationFiled: October 19, 2011Publication date: April 26, 2012Applicant: Bio-Ras Laboratories, Inc.Inventors: Steven T. Okino, Yan Wang
-
Publication number: 20120070877Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.Type: ApplicationFiled: December 1, 2011Publication date: March 22, 2012Applicant: Duke UniversityInventors: James J. Smith, Derek Jantz, Homme W. Hellinga
-
Patent number: 8137938Abstract: An L-amino acid is produced by culturing a bacterium belonging to the family Enterobacteriaceae, which is able to produce the L-amino acid, and is modified so that the activity of ribonuclease G is decreased in a medium containing glycerol as the carbon source, and collecting the L-amino acid from the culture.Type: GrantFiled: March 30, 2010Date of Patent: March 20, 2012Assignee: Ajinomoto Co., Inc.Inventors: Yuri Nagai, Yoshihiro Usuda
-
Publication number: 20120065148Abstract: The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs.Type: ApplicationFiled: May 11, 2010Publication date: March 15, 2012Applicants: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW, KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Ralf Hoffmann, Miles Douglas Houslay, David James Peter Henderson
-
Publication number: 20120065100Abstract: The present invention relates to phosphodiesterase 9A (PDE9A) for use as a marker for prostate cancer, and the use of PDE9A as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer.Type: ApplicationFiled: May 11, 2010Publication date: March 15, 2012Applicants: THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW, KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Ralf Hoffmann, Miles Douglas Houslay, David James Peter Henderson
-
Publication number: 20120045816Abstract: Provided herein are glycosylated polypeptide compositions with substantially reduced Neu5Gc content. The glycosylated polypeptides compositions with substantially reduced Neu5Gc content can be obtained from cell sources cultured with Neu5Gc competitor or from non-human animal sources fed a diet supplemented with Neu5Gc competitor. Also provided herein are methods of treating a human subject with said compositions.Type: ApplicationFiled: July 14, 2011Publication date: February 23, 2012Inventors: Darius Ghaderi, Ajit Varki
-
Publication number: 20120045797Abstract: The invention provides methods for amplification of polynucleotide sequences using primers containing single-Cstranded RNA. The methods employ use of an enzyme capable of cleaving single-stranded RNA, such as RNase I, to degrade a first RNA-containing primer prior to addition of a second RNA-containing primer. The invention also provides compositions and kits pl. for practicing the amplification methods, as well as methods which use the amplification products.Type: ApplicationFiled: May 9, 2011Publication date: February 23, 2012Applicant: Nugen Technologies, Inc.Inventors: Nurith Kurn, Shenglong Wang
-
Patent number: 8119382Abstract: Methods are provided for making restriction endonucleases with reduced star activity by one or more targeted mutations to a catalytic site within the restriction endonuclease. Examples of modifications to restriction endonucleases with significant sequence identity with KpnI are provided and reduced star activity demonstrated.Type: GrantFiled: August 18, 2006Date of Patent: February 21, 2012Assignees: New England Biolabs, Inc., Indian Institute of ScienceInventors: Valakunja Nagaraja, Matheshwaran Saravanan, Zhenyu Zhu
-
Publication number: 20120028312Abstract: The present invention concerns methods and compositions involving RNase III and polypeptides containing RNase III domains to generate RNA capable of triggering RNA-mediated interference (RNAi) in a cell. In some embodiments, the RNase III is from a prokaryote. RNase III activity will cleave a double-stranded RNA molecule into short RNA molecules that may trigger or mediate RNAi (siRNA). Compositions of the invention include kits that include an RNase III domain-containing polypeptide. The present invention further concerns methods using polypeptides with RNase III activity for generating RNA molecules that effect RNAi, including the generation of a number of RNA molecules to the same target.Type: ApplicationFiled: August 2, 2011Publication date: February 2, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Lance P. Ford, David Brown
-
Publication number: 20120009173Abstract: This invention relates to cytotoxic variants of human ribonuclease 1 (RNase 1) identified through analysis of the interaction between RNase 1 and the human ribonuclease inhibitor (hRI) as defined by the three dimensional (3-D) atomic structure of the RNase1 hRI complex. Also disclosed is the 3-D structure of the hRI•RNase 1 complex and methods for designing the RNase 1 variants.Type: ApplicationFiled: September 23, 2011Publication date: January 12, 2012Inventors: Ronald T. Raines, George N. Philllips, JR., R. Jeremy Johnson, Jason G. McCoy
-
Patent number: 8093061Abstract: Provided herein are methods for determining potency of RNAi agents. Such methods include, but are not limited to, cell-based and cell-free assays that measure binding of an RNAi agent with Ago2 or that measure Ago2 activity in the presence of such RNAi agents. Also provided are assays that determine potency of RNAi agents by assessing their ability to compete with other RNAi agents, including control RNAi agents, for binding and/or activation of Ago2.Type: GrantFiled: October 18, 2007Date of Patent: January 10, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: Walter F Lima, Timothy Vickers, Stanley T Crooke
-
Publication number: 20110321197Abstract: A method for producing a plant with increased yield as compared to a corresponding wild type plant whereby the method comprises at least the following step: increasing or generating in a plant or a part thereof one or more activities selected from the group consisting of 17.6 kDa class I heat shock protein, 26.Type: ApplicationFiled: October 2, 2009Publication date: December 29, 2011Applicant: BASF Plant Science GmbHInventors: Hardy Schön, Oliver Thimm, Gerhard Ritte, Oliver Bläsing, Koen Bruynseels, Yves Hatzfeld, Valerie Frankard, Ana Isabel Sanz Molinero, Christophe Reuzeau, Steven Vandenabeele
-
Publication number: 20110318811Abstract: Compositions and method for making and using a synthetic bovine DNase I are disclosed. More particularly, the sbDNase I of the present invention is a versatile enzyme that cleaves DNA nonspecifically to release 5?-phosphorylated nucleotides. The sbDNase I molecules of the present invention find particular use in a wide range of molecular biology applications, including: degradation of contaminating DNA after RNA isolation; RNA clean-up prior to, or in conjunction with, RT-PCR after in vitro transcription; identification of protein binding sequences on DNA (DNase I footprinting); prevention of clumping when handling cultured cells; tissue dissociation and creation of fragmented DNA for in vitro recombination reactions.Type: ApplicationFiled: May 9, 2011Publication date: December 29, 2011Applicant: APPLIED BIOSYSTEMS, LLCInventors: Gary Latham, Jon Kemppainen
-
Publication number: 20110287514Abstract: This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity.Type: ApplicationFiled: July 11, 2011Publication date: November 24, 2011Inventors: Ronald T. Raines, Julie C. Mitchell, Thomas J. Rutkoski
-
Publication number: 20110274704Abstract: The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction.Type: ApplicationFiled: August 30, 2010Publication date: November 10, 2011Applicants: IBC PHARMACEUTICALS, INC., IMMUNOMEDICS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Patent number: 8048664Abstract: Compositions and methods are provided that relate to a modified DNA cleaving enzyme having at least 35% amino acid sequence identity with T7 Endo I. The modified enzyme includes two catalytic centers separated by a ?-bridge where the ?-bridge contains at least one mutation having an effect of altering enzyme cleavage activity compared to the unmodified enzyme. Activities associated with the modified DNA cleaving enzyme that can be modulated in different reaction conditions include at least one of: (a) non-sequence specific nicking activity; (b) cleaving the second strand of a duplex DNA at a preexisting nick site to produce a linear duplex with a single strand overhang; (c) non-sequence specific DNA cleavage; (d) cleaving DNA flanking a mismatch; and (e) cleavage at a cruciform structure in a DNA duplex.Type: GrantFiled: November 18, 2010Date of Patent: November 1, 2011Assignee: New England Biolabs, Inc.Inventors: Chudi Guan, Sanjay Kumar, Rebecca Kucera
-
Publication number: 20110262422Abstract: The invention provides a method of treatment of any disorder in which administration of angiogenin is beneficial wherein the angiogenin is administered orally. Particularly, the oral angiogenin does not require a carrier or excipient or for the protein to be encapsulated or subjected to any other mechanism to improve its oral bioavailability.Type: ApplicationFiled: May 14, 2009Publication date: October 27, 2011Applicants: MURRAY GOULBURN CO-OPERATIVE CO., LIMITED, AGRICULTURE VICTORIA SERVICES PTY LTD.Inventors: Benjamin Cocks, Angus Tester, Peter Hobman, Matthew McDonagh
-
Publication number: 20110256537Abstract: Described herein are oligonucleotides useful for screening, detecting, isolating, quantitating, monitoring and sequencing of viruses and host biomarkers associated with prostate cancer and methods and kits of using the described oligonucleotides.Type: ApplicationFiled: April 12, 2011Publication date: October 20, 2011Inventors: Alice A. Jacobs, Chesley Leslin, David L. Dolinger
-
Patent number: 8039687Abstract: The present invention provides a method for selecting genomic DNA fragments which are useful for providing a plant with an agriculturally advantageous improvement. The method of the present invention comprises the steps of: 1) preparing genomic DNA from a plant, which is then cloned into a cloning vector to form a genomic DNA library; 2) introducing a genomic fragment from each of the genomic clones constituting the genomic DNA library separately into a plant to produce transgenic plants; 3) cultivating the transgenic plants or progeny thereof to select a plant exhibiting an agriculturally advantageous phenotypic variation; and 4) selecting the genomic DNA fragment, which was introduced in step (2) into the plant selected in step (3), as a purposed genomic DNA fragment.Type: GrantFiled: October 22, 2004Date of Patent: October 18, 2011Assignee: Japan Tobacco Inc.Inventors: Tomoaki Kubo, Toshihiko Komari, Satoru Usami, Yoshimitsu Takakura, Yukoh Hiei, Yuji Ishida
-
Patent number: 8039240Abstract: The cloning and heterologous expression of human T2 RNase6PL are disclosed. Further disclosed are methods for preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The methods are effected by administering to the subject a therapeutically effective amount of a RNase6PL ribonuclease or close homologues thereof.Type: GrantFiled: September 28, 2005Date of Patent: October 18, 2011Assignee: Yissum Reseach Development Company of the Hebrew University of JerusalemInventors: Levava Roiz, Betty Schwartz, Patricia Smirnoff, Oded Shoseyov
-
Publication number: 20110251094Abstract: The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods.Type: ApplicationFiled: April 13, 2011Publication date: October 13, 2011Applicant: Pronota N.V.Inventor: Koen Kas
-
Patent number: 8034598Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.Type: GrantFiled: June 23, 2009Date of Patent: October 11, 2011Assignee: Sangamo Biosciences, Inc.Inventor: Jeffrey C. Miller
-
Patent number: 8034998Abstract: The present invention relates to the regulation of reproductive development, particularly to the genetic ablation of reproductive tissues in angiosperm and gymnosperm species. Reproductive-preferred promoters, regulatory elements, and cytotoxic nucleotide sequences are disclosed herein, as are constructs and methods for genetic ablation.Type: GrantFiled: December 7, 2010Date of Patent: October 11, 2011Assignee: Arborgen Inc.Inventors: William H. Rottmann, Kim H. Norris-Caneda, Chunsheng Zhang
-
Patent number: 8034597Abstract: A polypeptide having an endonuclease activity derived from a psychrophilic microorganism Shewanella sp. strain Ac10, which exhibits high activity at low temperatures, can remove any nucleic acid present in a protein solution and can reduce the viscosity of a protein extract; and a nucleic acid encoding the polypeptide.Type: GrantFiled: March 8, 2006Date of Patent: October 11, 2011Assignee: Takara Bio Inc.Inventors: Naoyuki Awazu, Toshihiro Shodai, Hikaru Takakura, Masanari Kitagawa, Hiroyuki Mukai, Ikunoshin Kato
-
Patent number: 8029782Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.Type: GrantFiled: October 1, 2009Date of Patent: October 4, 2011Assignee: Quintessence Biosciences, Inc.Inventors: Tony Klink, John Kink, Laura Strong
-
Patent number: 8017356Abstract: A polypeptide having a endoribonuclease activity; a nucleic acid encoding the polypeptide; recombinant DNA having the nucleic acid therein; a transformant transformed with the recombinant DNA; a process for producing the polypeptide comprising the steps of cultivating the transformant and collecting the polypeptide from the culture; a process for producing a digest of single-stranded RNA comprising the step of reacting the polypeptide with the single-stranded RNA; and a method for the digestion of single-stranded RNA.Type: GrantFiled: July 4, 2006Date of Patent: September 13, 2011Assignee: Takara Bio Inc.Inventors: Masamitsu Shimada, Masanori Takayama, Kiyozo Asada, Ikunoshin Kato
-
Publication number: 20110217739Abstract: Provided herein are methods for cleaving a target RNA polynucleotide. The target RNA polynucleotide includes a Cas6 recognition domain and a cleavage site, and may be based on a repeat from a CRISPR locus. The methods may be practiced in vivo or in vitro. Also provided are polypeptides that have Cas6 endoribonuclease activity in the presence of a target RNA polynucleotide, and methods for using the polypeptides.Type: ApplicationFiled: November 5, 2009Publication date: September 8, 2011Applicant: University of Georgia Research Foundation, Inc.Inventors: Rebecca M. Terns, Michael P. Terns, Jason Carte
-
Patent number: 8008055Abstract: Polypeptides having an RNase H activity highly useful in genetic engineering; genes encoding these polypeptides; and a process for genetic engineeringly producing these polypeptides.Type: GrantFiled: August 19, 2008Date of Patent: August 30, 2011Assignee: Takara Bio Inc.Inventors: Takashi Uemori, Yoshimi Sato, Nobuto Koyama, Ryo Hirano, Hikaru Takakura, Hiroshi Kobori, Yuji Hashimoto, Kikyozo Asada, Ikunoshin Kato
-
Publication number: 20110195426Abstract: The present invention is partly based on the discovery that adverse factors can prevent an effective extraction of nucleic acids from a biological sample and that novel and unexpected agents and steps may be used to mitigate or remove the adverse factors, thereby dramatically improving the quality of the extracted nucleic acids. As such, one aspect of this invention is a novel method for extracting high quality nucleic acids from a biological sample. The high quality extractions obtained by the novel methods described herein are characterized by high yield and high integrity, making the extracted nucleic acids useful for various applications in which high quality nucleic acid extractions are preferred, e.g., a diagnosis, prognosis or therapy evaluation for a medical condition.Type: ApplicationFiled: July 16, 2010Publication date: August 11, 2011Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Leileata M. Russo, Kevin C. Miranda, Johan Skog
-
Publication number: 20110167519Abstract: The subject invention concerns polynucleotides encoding a small subunit of plant AGP having one or more mutations in the amino acid sequence wherein the mutation confers increased heat stability to the expressed AGP enzyme. Mutations in the N-terminus of the small subunit of heat labile plant AGP results in AGP enzymes that are significantly more heat stable compared to wild type AGP in that the mutant AGP retains significant levels of enzymatic activity following exposure to heat treatment. In one embodiment, the polynucleotide encodes a mutant small subunit of maize AGP. The subject invention also concerns methods for providing a plant with increased resistance to heat conditions. Plants with heat labile AGP can be transformed with a polynucleotide of the present invention. The subject invention also concerns these transformed plants and transgenic progeny thereof. The subject invention also concerns mutant polypeptides encoded by polynucleotides of the present invention.Type: ApplicationFiled: August 18, 2004Publication date: July 7, 2011Applicant: UNIVERSITY OF FLORIDAInventors: L. Curtis Hannah, Carla R. Lyerly Linebarger
-
Publication number: 20110158905Abstract: Disclosed herein are methods and compositions dock and lock (DNL) complexes comprising an AD moiety selected from an AKAP protein and a DDD moiety selected from a protein kinase A regulatory subunit. Also disclosed are fusion proteins comprising an AD moiety or DDD moiety attached to an effector moiety. The DDD moieties form dimers that bind to the AD moiety to form the DNL complexes. The effector moieties may be selected from a wide range of known effector moieties that produce one or more physiological effects, including but not limited to cell death. The DNL complexes may further comprise one or more diagnostic and/or therapeutic agents. The DNL complexes are of use for treating and/or diagnosing a variety of diseases or conditions.Type: ApplicationFiled: February 28, 2011Publication date: June 30, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: David M. Goldenberg, Chien-Hsing Chang
-
Publication number: 20110150875Abstract: The present invention provides, in part, methods and compositions for treating lipid disorders comprising administering a polypeptide that inhibits PCSK9. A novel method for identifying polypeptides that interact with PCSK9 is also provided.Type: ApplicationFiled: May 21, 2009Publication date: June 23, 2011Inventors: Qing Zhang, Nicholas J. Murgolo, Joseph A. Hedrick
-
Patent number: 7960159Abstract: The present invention is a method for detecting DNA sequence differences including single nucleotide mutations or polymorphisms, one or more nucleotide insertions, and one or more nucleotide deletions. Labeled heteroduplex PCR fragments containing base mismatches are prepared. Endonuclease cleaves the heteroduplex PCR fragments both at the position containing the variation (one or more mismatched bases) and to a lesser extent, at non-variant (perfectly matched) positions. Ligation of the cleavage products with a DNA ligase corrects non-variant cleavages and thus substantially reduces background. This is then followed by a detection step in which the reaction products are detected, and the position of the sequence variations are determined.Type: GrantFiled: September 2, 2010Date of Patent: June 14, 2011Assignee: Corneil Research Foundation, Inc.Inventors: Francis Barany, Weiguo Cao, Jianmin Huang, Jing Lu
-
Patent number: 7951927Abstract: The present invention refers to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using a member of the human mariner transposases. The invention further refers to this transposase and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or IR/DRs). Furthermore, applications of this gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.Type: GrantFiled: March 31, 2006Date of Patent: May 31, 2011Assignee: Max-Delbrück Centrum für Molekulare MedizinInventors: Csaba Miskey, Zoltan Ivics
-
Publication number: 20110123514Abstract: The invention provides methods for enriching a milk extract for angiogenin, such methods involving separation by size, charge or immunoaffinity. The invention also provides the angiogenin enriched extract produced by the methods and provides them in pharmaceutical and neutraceutical compositions and foods for treating a variety of diseases or disorders that can be treated by angiogenin.Type: ApplicationFiled: May 14, 2009Publication date: May 26, 2011Inventors: Matthew McDonagh, Benjamin Cocks, Angus Tester, Peter Hobman, Andrew Brown
-
Publication number: 20110117610Abstract: A modified Dicer polypeptide is provided, which modified Dicer polypeptide exhibits enhanced catalytic activity. Also provided is a method for producing small regulatory RNAs from a dsRNA, involving contacting a dsRNA with a subject modified Dicer. Small regulatory RNAs produced by a subject method find use in a variety of applications, including research and therapeutic applications.Type: ApplicationFiled: March 18, 2009Publication date: May 19, 2011Inventors: Jennifer Doudna, Enbo Ma, Ian J. Macrae
-
Publication number: 20110111409Abstract: The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.Type: ApplicationFiled: November 5, 2010Publication date: May 12, 2011Inventors: Dominick Sinicropi, John Morlan
-
Patent number: 7935509Abstract: Methods and compositions are provided that relate to obtaining a recombinant DNA and RNA cleaving nuclease. This involves the over-expression of a fusion protein between maltose-binding protein and a truncated nuclease in a soluble form in the cytoplasm of a host cell from which it can be readily extracted.Type: GrantFiled: August 12, 2005Date of Patent: May 3, 2011Assignee: New England Biolabs, Inc.Inventor: Pei-Chung Hsieh
-
Publication number: 20110086409Abstract: A method for making a surfactant-based monolithic column is provided. The method comprises providing a mixture comprising at least one surfactant monomer, at least one crosslinker, at least one initiator, and at least one porogen and polymerizing the mixture to form the surfactant-based monolithic column. The present disclosure also provides a surfactant-based monolithic column, a method for separating molecules, and a process for preparing a surfactant monomer.Type: ApplicationFiled: March 30, 2009Publication date: April 14, 2011Inventors: Shahab Ahmed Shamsi, Jun He, Congying Gu